Trellis Bioscience, Inc.

Yale University

Altimab Therapeutics, Inc.

Bo Chen

Lawrence M Kauvar

Krista Maureen McCutcheon

William Usinger

Ying-Ping Jiang

Minha Park

Stote Ellsworth

Orit Foord

Fen Zhang

Gizette Sperinde

Dianqing Wu

Chun Wu

Zijuan Li

Hai Wu

Jun Bao

The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Humanized anti-DKK2 antibody and uses thereof

Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

Antibodies useful in passive influenza immunization

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

High affinity human antibodies to human cytomegalovirus (CMV) gB protein

High affinity human antibodies to human cytomegalovirus (CMV) GB protein

Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided.

Protein complexes for antigen binding and methods of use

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

Growing community of inventors

Daly City, CA, United States of America

Bo Chen